Provided by Tiger Trade Technology Pte. Ltd.

Jade Biosciences

20.84
-0.4500-2.11%
Volume:357.94K
Turnover:7.51M
Market Cap:1.33B
PE:-8.89
High:21.40
Open:21.07
Low:20.81
Close:21.29
52wk High:28.00
52wk Low:6.91
Shares:63.60M
Float Shares:47.12M
Volume Ratio:0.72
T/O Rate:0.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3433
EPS(LYR):-3.1931
ROE:-89.18%
ROA:-33.59%
PB:0.46
PE(LYR):-6.53

Loading ...

Jade Biosciences (JBIO) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Apr 06

Jade Biosciences Adopts 2026 Employment Inducement Stock Plan

TIPRANKS
·
Apr 03

Jade Biosciences launches inducement equity plan, reserves 1.75 million shares

Reuters
·
Apr 03

Jade Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 25

Jade Biosciences participates in a conference call with William Blair

TIPRANKS
·
Mar 19

Analysts Are Bullish on Top Healthcare Stocks: Jade Biosciences (JBIO), Hyperfine (HYPR)

TIPRANKS
·
Mar 19

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO) and Tonix Pharma (TNXP)

TIPRANKS
·
Mar 16

Jade Biosciences Inc : Btig Raises Target Price to $39 From $28

THOMSON REUTERS
·
Mar 16

Jade Biosciences Is Maintained at Buy by BTIG

Dow Jones
·
Mar 16

Jade Biosciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 11

Jade Biosciences price target raised to $23 from $17 at Guggenheim

TIPRANKS
·
Mar 11

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO) and Dyne Therapeutics (DYN)

TIPRANKS
·
Mar 10

Jade Biosciences Price Target Maintained With a $24.00/Share by Wedbush

Dow Jones
·
Mar 09

William Blair Initiates Coverage on Jade Biosciences With Outperform Rating

MT Newswires Live
·
Mar 09

Positioning Jade Biosciences as a Leading APRIL Inhibitor Play in IgA Nephropathy With Compelling Pipeline and Risk‑Reward

TIPRANKS
·
Mar 07

Jade Biosciences price target raised to $40 from $19 at Stifel

TIPRANKS
·
Mar 07

Jade Biosciences Q4 EPS $(0.11) Beats $(0.49) Estimate

Benzinga Earnings
·
Mar 06

BRIEF-Jade Biosciences Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Update

Reuters
·
Mar 06

Jade Biosciences Q4 R&D expenses rise to USD 28.5 million (+61.9%)

Reuters
·
Mar 06

Jade Biosciences Inc: Expects to Initiate a Phase 2 Clinical Trial in Patients With Igan Mid-2026, With Preliminary Data Anticipated in 2027

THOMSON REUTERS
·
Mar 06